Britain and America have concluded a key bilateral deal that will keep zero levies on British pharmaceutical exports going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This commitment guarantees that duties on these key goods will be held at zero for a duration of the next three years.
This development comes after recent statements to hike tariffs on patented drug products, with increases floated reaching double the cost.
"This agreement between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Importance
Drugs constitute one of the the United Kingdom's largest exports to the US, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to the third quarter, the UK exported medicines valued at over eleven billion pounds to the US. This figure made up a significant portion of total UK exports in that span.
"This guarantee secures jobs, stimulates funding and paves the way for the UK to become a global hub for life sciences," a government official commented.
Key UK Commitments
The agreement entails several specific changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be capped at 15%. Last year, refunds were more than twenty percent.
Broader Context
The deal comes amid a long-running row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were intensified by claims that American patients were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or scrapped, while major expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
